Skip to main content
Quest Diagnostics Home

KRAS G12C Mutation: An Emerging Biomarker for NSCLC

Date: Monday, Jan 4, 2021

Description: Presented by Yuri Fesko, MD and Kari Hooper, MD.

Authors: 

Fesko, Yuri, MD
Chief Clinical Officer, Oncology Quest Diagnostics
Secaucus, New Jersey

Hooper, Kari, MD
Pathologist, AmeriPath®/Quest Diagnostics; Department Chair,
Integris Baptist Medical Center Oklahoma City, Oklahoma

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.